Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMelrose Regulatory News (MRO)

Share Price Information for Melrose (MRO)

Share Price is delayed by 15 minutes
Get Live Data
453.70    -5.90 (-1.28%)
Bid:
454.70
Ask:
454.90
Spread: 0.20 (0.044%)
Market Cap: £5.65b
MRO Live PriceLast checked at - London Stock Exchange

Intraday Melrose Share Chart

Disposal

6 Jun 2022 07:00

RNS Number : 6934N
Melrose Industries PLC
06 June 2022
 

3 June 2022

MELROSE INDUSTRIES PLC

 

SALE OF ERGOTRON

 

Sale of Ergotron

Melrose Industries PLC ("Melrose", the "Company" or the "Group") has entered into an agreement to sell its Ergotron business ("Ergotron"), to funds managed by The Sterling Group ("Sterling") for total consideration of approximately $650 million (c.£520 million), payable in cash on completion (the "Disposal"). Ergotron is a leading designer, manufacturer and distributor of ergonomic products for use in a variety of working, learning and healthcare environments, with gross assets (mostly goodwill) as at 31 December 2021 of £617 million and 2021 adjusted operating profit of £58 million (2021 EBITDA £62 million). 

Completion of the Disposal is expected to occur in the third quarter of 2022 ("Completion") and is conditional upon customary US antitrust approvals. On or before Completion, Melrose will announce how it intends to use the net proceeds from the Disposal. 

 

Successful execution of Melrose's strategy for Nortek

Having sold the Nortek Air Management and Nortek Control businesses last year, Ergotron is the last of the businesses remaining from the Nortek Inc acquisition in 2016. On Completion, Melrose will have more than doubled shareholders' initial investment, whilst transforming the Nortek businesses themselves.

Refocusing them away from unprofitable work, Melrose made the significant investment necessary to implement operational best practices, increase R&D, develop new products and build stronger customer relationships. These actions resulted in an almost doubling of adjusted operating margins and ensured each business remained highly cash generative, with over $1 billion generated during Melrose ownership.

This strong support and appropriate investment under Melrose ownership unlocked the potential of all the Nortek businesses and set them on the path for further success under new owners for the next stage of their development. 

 

Simon Peckham, Chief Executive of Melrose, today said:

"The sale of Ergotron is the final step in our Nortek ownership cycle, capping what has been a very successful acquisition for Melrose shareholders. We will have more than doubled shareholders' equity investment in Nortek and have transformed the businesses themselves. Our attention now remains firmly on achieving the same result for the current Group." 

 

Enquiries:

Investor Relations:

+44 (0) 7974 974690

ir@melroseplc.net

 

Montfort Communications - Financial PR:

+44 (0) 20 3514 0897

Nick Miles miles@montfort.london

+44 (0) 7739 701634

Charlotte McMullen mcmullen@montfort.london

+44 (0) 7921 881 800

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISBCGDLXXGDGDU
Date   Source Headline
30th Jul 20247:00 amRNSTransaction in Own Shares
29th Jul 20247:00 amRNSTransaction in Own Shares
26th Jul 20247:00 amRNSTransaction in Own Shares
25th Jul 20247:00 amRNSTransaction in Own Shares
24th Jul 20247:00 amRNSTransaction in Own Shares
23rd Jul 20247:00 amRNSTransaction in Own Shares
22nd Jul 20247:00 amRNSTransaction in Own Shares
19th Jul 202410:36 amRNSTransaction in Own Shares
18th Jul 20247:00 amRNSTransaction in Own Shares
17th Jul 20247:00 amRNSTransaction in Own Shares
16th Jul 20247:00 amRNSTransaction in Own Shares
15th Jul 20247:00 amRNSTransaction in Own Shares
12th Jul 20247:00 amRNSTransaction in Own Shares
11th Jul 20243:45 pmRNSReduction of Capital
11th Jul 20249:00 amRNSDirector Declaration
11th Jul 20247:00 amRNSTransaction in Own Shares
10th Jul 20247:00 amRNSTransaction in Own Shares
9th Jul 20247:00 amRNSTransaction in Own Shares
8th Jul 20247:00 amRNSTransaction in Own Shares
5th Jul 20247:00 amRNSTransaction in Own Shares
4th Jul 20247:00 amRNSTransaction in Own Shares
3rd Jul 20247:00 amRNSTransaction in Own Shares
2nd Jul 20247:00 amRNSTransaction in Own Shares
1st Jul 20247:00 amRNSTransaction in Own Shares
28th Jun 20247:00 amRNSTransaction in Own Shares
27th Jun 20247:00 amRNSTransaction in Own Shares
26th Jun 20247:00 amRNSTransaction in Own Shares
25th Jun 20247:00 amRNSTransaction in Own Shares
24th Jun 20247:00 amRNSTransaction in Own Shares
21st Jun 20247:00 amRNSTransaction in Own Shares
20th Jun 20247:00 amRNSTransaction in Own Shares
19th Jun 20247:00 amRNSTransaction in Own Shares
18th Jun 20247:00 amRNSDirectorate Change
18th Jun 20247:00 amRNSTransaction in Own Shares
17th Jun 20247:00 amRNSTransaction in Own Shares
14th Jun 20247:00 amRNSTransaction in Own Shares
13th Jun 20247:00 amRNSTransaction in Own Shares
12th Jun 20247:00 amRNSTransaction in Own Shares
11th Jun 20245:30 pmRNSDirector/PDMR Shareholding
11th Jun 20247:00 amRNSTransaction in Own Shares
10th Jun 20247:00 amRNSTransaction in Own Shares and Correction Statement
7th Jun 20247:00 amRNSTransaction in Own Shares
6th Jun 20249:30 amRNSHolding(s) in Company
6th Jun 20247:00 amRNSTransaction in Own Shares
5th Jun 20247:00 amRNSTransaction in Own Shares
4th Jun 20247:00 amRNSTransaction in Own Shares
3rd Jun 20247:06 amRNSDirector/PDMR Shareholding and TVR
3rd Jun 20247:00 amRNSTransaction in Own Shares
31st May 20247:00 amRNSTransaction in Own Shares
30th May 20249:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.